Effect of macrophages transduced with an adenoviral vector expressing interleukin-12 in prostate cancer

表达白介素 12 的腺病毒载体转导的巨噬细胞对前列腺癌的影响

• 批准号: 15591712
• 负责人: IWAMURA Masatsugu
• 金额: $ 1.73万
• 依托单位: Kitasato University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2003
• 资助国家: 日本
• 起止时间: 2003 至 2004
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-15591712/
• 关键词: Interleukin-12; Macrophages; Prostate cancer; Immunomofulatory approaches; 米国

For advanced prostate cancer, the standard therapy is androgen ablation, which largely palliative and it is critical to develop additional therapies that are effective against systemic disease to complement current treatments for localized prostate cancer. Novel approaches, such as immunogene therapy, provide opportunities to achieve these goals.We investigated the efficacy of macrophages transduced with murine IL-12 recombinant adenoviral vector (AdmIL-12) using the 178-2 BMA mouse prostate cancer model. AdmIL-12-transduced macrophages secreted IL-12 in vitro and there were no significant differences in cell number at any MOI. Uninfected macrophages and Adβgal-infected macrophages produced very low levels of IL-12 at 24h and 48h, whereas a dose- and time- dependent increase in secretion of mIL-12 was detected in the AdmIL-12-infected macrophages. Cytometric analysis showed that AdmIL-12-infected macrophages had an 2 fold increase in surface expression of MHC class I and II molecules and F4/80 antigen compared with uninfected macrophages. Adβgal-infected macrophages were similar to uninfected macrophages except that increased MHC class II expression was observed. According to these results, we have demonstrated successful genetic modification of murine peritoneal exudates macrophages with adenoviral vectors and this therapeutic approach may induced substantial systemic antitumor immunological responses, hopefully. For next step to determine possible therapeutic activities AdmIL-12 transduced macrophages, we are going to set up preclinical experiment using an orthotopic mouse model of metastatic prostate cancer.

对于晚期前列腺癌，标准治疗是雄激素消融，这在很大程度上是姑息性的，关键是要开发对全身性疾病有效的其他治疗方法，以补充目前对局限性前列腺癌的治疗。新的方法，如免疫基因治疗，提供了机会，以实现这些目标。我们研究了与小鼠IL-12重组腺病毒载体（AdmIL-12）转导的巨噬细胞使用178-2 BMA小鼠前列腺癌模型的疗效。AdmIL-12转导的巨噬细胞在体外分泌IL-12，并且在任何MOI下细胞数量均无显著差异。未感染的巨噬细胞和Adβ gal感染的巨噬细胞在24小时和48小时产生非常低水平的IL-12，而在AdmIL-12感染的巨噬细胞中检测到mIL-12分泌的剂量和时间依赖性增加。流式细胞术分析表明，AdmIL-12感染的巨噬细胞的表面表达的MHC I类和II类分子和F4/80抗原相比，未感染的巨噬细胞增加了2倍。Adβ gal感染的巨噬细胞与未感染的巨噬细胞相似，不同之处在于观察到MHC II类表达增加。根据这些结果，我们已经证明了成功的基因修饰的小鼠腹腔渗出液巨噬细胞与腺病毒载体和这种治疗方法可能会诱导大量的全身抗肿瘤免疫反应，希望。对于确定AdmIL-12转导的巨噬细胞的可能治疗活性的下一步，我们将使用转移性前列腺癌的原位小鼠模型建立临床前实验。

项目成果

Current statues of gene therapy for urological cancer

泌尿系癌症基因治疗的现状

• 期刊: Gene Therapy in Cancer (accepted)
• 作者: Matsumoto K;Irie A;et al.
• 通讯作者: et al.

Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy

• DOI: 10.1016/j.urology.2005.01.051
• 发表时间: 2005-07-01
• 期刊: UROLOGY
• 影响因子: 2.1
• 作者: Satoh, T;Matsumoto, K;Baba, S
• 通讯作者: Baba, S

Immunomodulatory gene therapy for prostate cancer : Current outcome and future directions.

前列腺癌的免疫调节基因治疗：当前结果和未来方向。

• 期刊: TRANSWORLD RESEARCH NETWORK (in press)
• 作者: Satoh T;Iwamura M et al.
• 通讯作者: Iwamura M et al.

佐藤 威文 他: "In situ gene therapy for prostate cancer."Current Gene Therapy.. (in press).

Takefum​​i Sato 等人：“前列腺癌的原位基因治疗。”当前基因治疗..（正在印刷中）。

Laparoscopic pyeloplasty for ureteropelvic junction obatruction : Outcome of initial 12 procedures.

腹腔镜肾盂成形术治疗肾盂输尿管连接部梗阻：最初 12 次手术的结果。

• 发表时间: 2004
• 期刊: Int J Urol. 11
• 作者: Iwamura M;Soh S;et al.
• 通讯作者: et al.